Business Wire

IFF Details Sustainability Leadership in 2023 Do More Good Report

Share

IFF (NYSE:IFF) today released its 2023 Do More Good Report, describing how the Company is progressing against its environmental, social, governance, and sustainable solutions (or ESG+) strategy across the organization. The report showcases that IFF enabled customers and consumers to avoid approximately 24.6 million tonnes of CO2e emissions using IFF innovations, amongst other achievements. The new report can be experienced by visiting iff.com/domoregoodreport.

“Sustainability for us at IFF is more than just a cost of doing business today – it drives everything we do,” said Erik Fyrwald, IFF CEO. “Our passion for sustainable innovation, coupled with ambitious target-setting is vital in helping our customers achieve their sustainability goals and targets.”

This new report marks the third year following the 2021 launch of the Company’s Do More Good™ Plan, which strategically positions IFF to amplify industry-wide and societal change toward sustainable development. The Plan is built upon four pillars: Sustainable Solutions, Climate & Planetary Health, Equity & Wellbeing, and Transparency & Accountability. The Do More Good Report lays out IFF’s achievements in each respective pillar. Furthermore, the most recent disclosures are organized according to the results of a double materiality¹ assessment commissioned by IFF to understand and identify the most important ESG topics impacting its business, along with the factors where IFF may also have an impact on society and the environment.

Key accomplishments from 2023 include:

  • ESG leadership recognition, such as qualifying as a constituent of the Dow Jones Sustainability Indices, North America, for the fourth consecutive year
  • Nine in-person human rights impact assessments completed for strategic supply chains in six countries
  • 21% reduction in Scope 1 and 2 GHG emissions below 2021 baseline levels
  • Ten new IFF facilities achieved internal zero waste to landfill (ZWL) verification, totaling 51 ZWL major manufacturing facilities to date
  • No statistically relevant gender pay gap in 27 countries assessed through EDGE Move level global certification
  • 100% employee completion rate on annual business ethics training

The new report also includes examples of innovations led by sustainable thinking. For instance, IFF is one of the largest global buyers and harvesters of seaweed for hydrocolloids, which are essential ingredients in many foods, pharmaceuticals, fertilizers, and cosmetics. As part of its commitment to support members of the seaweed value-chain, IFF partnered with Bellona, an environmental NGO, to restore seaweed forests in northern Norway overtaken by more than 300 invasive species of sea urchins. Returning about 5,000 km² of urchin barrens back into vibrant kelp forests has inspired the visual graphics displayed in the 2023 report.

IFF retained an independent third party to assess whether the report presents a complete and balanced presentation of its sustainability activities and performance in accordance with the GRI Standards, and whether the 2023 information and data for specified indicators are fairly presented in accordance with the reporting criteria. IFF has annually issued a standards-adherent sustainability report since 2010. To learn more about past sustainability reporting at IFF, visit its report library. Also, use #DoMoreGoodxIFF to follow the conversation on social channels.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients, and solutions for products the world craves. Together, we will do more good for people and planet.Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

© 2024 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

Regarding Forward Looking Statements

Statements in this annual ESG+ Report that are not historical facts or information are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements should be evaluated with consideration given to the many risks and uncertainties inherent in the Company’s business that could cause actual results and events to differ materially from those in the forward-looking statements. Certain of such forward-looking information may be identified by such terms as “expect,” “anticipate,” “believe,” “outlook,” “may,” “estimate,” “should” and “predict” or similar terms or variations thereof. Such forward-looking statements are based on a series of expectations, assumptions, estimates and projections about the Company, are not guarantees of future results or performance, and involve significant risks, uncertainties, and other factors, including assumptions and projections, for all forward periods. Actual results of the Company may differ materially from any future results expressed or implied by such forward-looking statements. The Company intends its forward-looking statements to speak only as of the time of such statements and does not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions, or results. The Company can give no assurance that such expectations or forward-looking statements will prove to be correct. Any public statements or disclosures by IFF following this report that modify or impact any of the forward-looking statements contained in or accompanying this report will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this report.

¹ As further explained in its report, "materiality" used in IFF’s ESG reporting does not correspond to the concept of materiality used under U.S. securities law or other applicable laws and does not represent any determination by the Company that any of the content contained in this report is “material” for purposes of U.S. securities law or in the context of financial reporting or its financial results. 

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Paulina Heinkel 332.877.5339
media.request@iff.com

Investor Relations:
Michael Bender 212.708.7263
Investor.Relations@iff.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions21.6.2024 21:45:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented new data from its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). These updated data on 12 patients who received the full dose as a single infusion in Parts B and C of the trial are consistent with previously reported positive results in the VX-880 trial and reinforce the transformative potential of this therapy. At baseline, all patients in the study had undetectable fasting C-peptide (a marker of endogenous insulin secretion), a history of recurrent SHEs in the year prior to screening, and required an average of 39.3 (min, max; 19.8, 52.0) units of insulin per day. Following a single infusion of VX-880 at the full dose, all 12 patients demonstrated islet cell engraftment and glucose-responsive insulin production by Day 90. At the latest visi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye